Condition: Hereditary Angioedema (HAE) · Angioedema · Bradykinin-mediated Angioedema · Sponsor: Institute for Asthma and Allergy
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
This description comes directly from the study's public registry record.
Henry Li, MD · 301-962-5800 · info@allergyasthma.us
Always discuss trial participation with your own doctor first.
| Institute For Asthma & Allergy | Wheaton, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07046806